Literature DB >> 24518139

Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases.

Peter Seizer1, Meinrad Gawaz, Andreas E May.   

Abstract

Cyclophilin A (CyPA) is an abundantly expressed intracellular protein. It exerts a variety of functions due to its peptidyl-prolyl cis-trans isomerase (PPIase) activity. When released into the extracellular space, CyPA binds to its extracellular receptor CD147 (EMMPRIN) and thereby initiates a cascade of inflammatory processes. Recent data indicate that both extra- and intracellular CyPA significantly contribute to cardiovascular inflammation, myocardial ischaemia and reperfusion injury, and myocardial remodelling processes. Thus, CyPA appears to represent a novel target to treat vascular and myocardial inflammation.

Entities:  

Keywords:  Cyclophilin A; EMMPRIN; Inflammation

Mesh：

Substances：

Year:  2014        PMID： 24518139     DOI： 10.1093/cvr/cvu035

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


  23 in total

1.  Interaction of cyclophilin A with a novel binding protein, SR-25, and characterization of their expression pattern in Chinese hepatocellular carcinoma patients.

Authors:  Jian Chen; Ning Li; Peiwen Lian; Jiahui Wang; Peng Li; Zhaohua Gong; Lixin Jiang
Journal:  Oncol Lett       Date:  2016-11-07       Impact factor: 2.967

2.  Inhibition of the cyclophilin A-CD147 interaction attenuates right ventricular injury and dysfunction after acute pulmonary embolism in rats.

Authors:  Guangdong Lu; Zhenyu Jia; Qingquan Zu; Jinxing Zhang; Linbo Zhao; Haibin Shi
Journal:  J Biol Chem       Date:  2018-06-18       Impact factor: 5.157

Review 3.  Extracellular Vesicles in the Progression and Therapeutic Resistance of Nasopharyngeal Carcinoma.

Authors:  Yunhan Shan; Peijun Zhou; Qin Zhou; Lifang Yang
Journal:  Cancers (Basel)       Date:  2022-05-04       Impact factor: 6.575

Review 4.  Extracellular cyclophilins in health and disease.

Authors:  Michael Bukrinsky
Journal:  Biochim Biophys Acta       Date:  2014-11-18

5.  The Novel Extracellular Cyclophilin A (CyPA) - Inhibitor MM284 Reduces Myocardial Inflammation and Remodeling in a Mouse Model of Troponin I -Induced Myocarditis.

Authors:  David Heinzmann; Anna Bangert; Anna-Maria Müller; Saskia N I von Ungern-Sternberg; Frederic Emschermann; Tanja Schönberger; Madhumita Chatterjee; Andreas F Mack; Karin Klingel; Reinhard Kandolf; Miroslav Malesevic; Oliver Borst; Meinrad Gawaz; Harald F Langer; Hugo Katus; Gunter Fischer; Andreas E May; Ziya Kaya; Peter Seizer
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 6.  The roles of CD147 and/or cyclophilin A in kidney diseases.

Authors:  Xin Qu; Chunting Wang; Jicheng Zhang; Guoqiang Qie; Jianxin Zhou
Journal:  Mediators Inflamm       Date:  2014-12-17       Impact factor: 4.711

Review 7.  The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.

Authors:  Lijuan Xiong; Carl K Edwards; Lijun Zhou
Journal:  Int J Mol Sci       Date:  2014-09-29       Impact factor: 5.923

8.  Chemotactic Activity of Cyclophilin A in the Skin Mucus of Yellow Catfish (Pelteobagrus fulvidraco) and Its Active Site for Chemotaxis.

Authors:  Farman Ullah Dawar; Jiagang Tu; Yang Xiong; Jiangfeng Lan; Xing Xing Dong; Xiaoling Liu; Muhammad Nasir Khan Khattak; Jie Mei; Li Lin
Journal:  Int J Mol Sci       Date:  2016-08-29       Impact factor: 5.923

9.  Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus.

Authors:  Surya Ramachandran; Anandan Vinitha; Cheranellore Chandrasekharan Kartha
Journal:  Cardiovasc Diabetol       Date:  2016-11-03       Impact factor: 9.951

10.  EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial Infarction.

Authors:  Irene Cuadrado; Maria Jose Garcia Miguel Piedras; Irene Herruzo; Maria Del Carmen Turpin; Borja Castejón; Paula Reventun; Ana Martin; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza
Journal:  Theranostics       Date:  2016-02-15       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.